US · MOLN · BIOTECHNOLOGY
Molecular Partners AG (MOLN) intrinsic value and stock valuation
$2.53as of 2026-11-21 · Mkt cap 151.92M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Molecular Partners AG DCF and intrinsic value
InvestorsCraft values MOLN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MOLN’s statements →
Molecular Partners AG Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2013–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $4.97M | $7.04M | $189.6M | $9.33M |
| Operating income | -$-58.12M | -$-61.22M | -$-61.11M | $116.6M | -$-63.42M |
| Net income | -$-61.65M | -$-54.04M | -$-61.98M | $117.9M | -$-63.78M |
| EPSd | -$-1.65M | -$-1.59M | -$-1.89M | $3.54M | -$-2.06M |
| Operating cash flow | -$-51.26M | -$-59.25M | -$-59.01M | $118.6M | -$-90.95M |
| Capital expenditure | -$-710K | -$-720K | -$-570K | -$-1.42M | -$-1.31M |
| Free cash flow | -$-51.97M | -$-59.97M | -$-59.81M | $117.2M | -$-92.26M |
| Total assets | $102.1M | $158.5M | $198.4M | $262.3M | $172.7M |
| Total debt | $3.64M | $2.44M | $3.65M | $4.85M | $6.04M |
| Net debt | -$-79.01M | -$-61.43M | -$-63.66M | -$-83.1M | -$-65.77M |
| Total equity | $80.3M | $141.6M | $176.4M | $235.2M | $107.3M |
| Cash and short-term investments | $93.1M | $149.4M | $186.9M | $249.1M | $132.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $4.97M | $7.04M | $189.6M | $9.33M |
| Cost of revenue | $2.05M | $47.5M | $47.8M | $50.8M | $55.7M |
| Gross profit | -$-2.05M | -$-42.53M | -$-40.81M | $138.8M | -$-46.39M |
| Research and development expenses | $40.2M | $48.6M | $48.8M | $50.8M | $55.7M |
| Selling, general and administrative expenses | $14.9M | $17.2M | $19M | $21.8M | $16.9M |
| Other expenses | -$-4.17M | -$-47.09M | -$-47.48M | $370K | $120K |
| Operating expenses | $50.9M | $18.7M | $20.3M | $72.9M | $72.8M |
| Cost and expenses | $58.1M | $66.2M | $68.2M | $72.9M | $72.8M |
| Interest income | $1.52M | $3.38M | $4.28M | $1.2M | $110K |
| Interest expense | $20K | $30K | $50K | $650K | $610K |
| Depreciation and amortization | $2.14M | $2.37M | $2.42M | $2.39M | $2.56M |
| Ebitda | -$-59.49M | -$-51.65M | -$-59.52M | $119M | -$-60.66M |
| Operating income | -$-58.12M | -$-61.22M | -$-61.11M | $116.6M | -$-63.42M |
| Total other income/expenses, net | -$-3.52M | $7.18M | -$-880K | $1.24M | -$-360K |
| Income before tax | -$-61.65M | -$-54.04M | -$-61.98M | $117.9M | -$-63.78M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-61.65M | -$-54.04M | -$-61.98M | $117.9M | -$-63.78M |
| Weighted average shares outstanding | $37.3M | $34M | $32.8M | $32.5M | $31M |
| Weighted average diluted shares outstanding | $37.3M | $34M | $32.8M | $33.3M | $31M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $93.1M | $149.4M | $186.9M | $249.1M | $132.8M |
| Net receivables | $1.91M | $290K | $1.75M | $1.7M | $25.7M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $96.9M | $154.3M | $192.5M | $254.8M | $164.2M |
| Property, plant and equipment, net | $5.23M | $4.2M | $5.68M | $7.24M | $8.15M |
| Goodwill and intangible assets | $0.00 | $50K | $210K | $270K | $330K |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $5.23M | $4.25M | $5.89M | $7.51M | $8.48M |
| Total assets | $102.1M | $158.5M | $198.4M | $262.3M | $172.7M |
| Accounts payable | $940K | $680K | $410K | $1M | $4.86M |
| Short-term debt | $1.21M | $1.22M | $1.21M | $1.2M | $1.19M |
| Deferred revenue | $0.00 | $0.00 | $4.33M | $6.41M | $28.3M |
| Total current liabilities | $11M | $10.8M | $14.4M | $17.3M | $46.9M |
| Long-term debt | $2.44M | $1.23M | $2.44M | $3.65M | $4.85M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $3.64M | $6.92M |
| Total non-current liabilities | $10.8M | $6.11M | $7.51M | $9.84M | $18.5M |
| Capital lease obligations | $3.64M | $2.44M | $3.65M | $4.85M | $6.04M |
| Total liabilities | $21.8M | $16.9M | $21.9M | $27.1M | $65.4M |
| Common stock | $4.04M | $4.04M | $3.63M | $3.6M | $3.23M |
| Retained earnings | -$-311.75M | -$-246.29M | -$-191.75M | -$-127.78M | -$-250.95M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | -$-980K | $0.00 |
| Total equity | $80.3M | $141.6M | $176.4M | $235.2M | $107.3M |
| Total investments | $10.4M | $85.6M | $119.6M | $161.2M | $61M |
| Total debt | $3.64M | $2.44M | $3.65M | $4.85M | $6.04M |
| Net debt | -$-79.01M | -$-61.43M | -$-63.66M | -$-83.1M | -$-65.77M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-61.65M | -$-54.04M | -$-61.98M | $117.9M | -$-63.78M |
| Depreciation and amortization | $2.14M | $2.37M | $2.42M | $2.39M | $2.56M |
| Stock-based compensation | $4.42M | $4.11M | $5.21M | $5.09M | $4.08M |
| Change in working capital | $1.16M | -$-3.8M | -$-6.01M | -$-6.01M | -$-34.67M |
| Accounts receivable | $460K | -$-350K | -$-930K | $25.3M | -$-23.37M |
| Inventory | $0.00 | $0.00 | $0.00 | -$-19.93M | $21.7M |
| Accounts payable | $60K | $520K | -$-810K | -$-5.34M | $1.66M |
| Net cash provided by operating activities | -$-51.26M | -$-59.25M | -$-59.01M | $118.6M | -$-90.95M |
| Investments in property, plant and equipment | -$-710K | -$-700K | -$-810K | -$-1.42M | -$-1.31M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $370K |
| Net cash used for investing activities | $72.6M | $40.5M | $44.6M | -$-101.12M | -$-22.24M |
| Common stock issued | $60K | $17.3M | $30K | $250K | $51.5M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | -$-630K | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-1.15M | $14.4M | -$-1.17M | -$-1.57M | $50.6M |
| Net change in cash | $18.8M | -$-3.44M | -$-20.64M | $16.1M | -$-61.91M |
| Cash at end of period | $82.7M | $63.9M | $67.3M | $88M | $71.8M |
| Operating cash flow | -$-51.26M | -$-59.25M | -$-59.01M | $118.6M | -$-90.95M |
| Capital expenditure | -$-710K | -$-720K | -$-570K | -$-1.42M | -$-1.31M |
| Free cash flow | -$-51.97M | -$-59.97M | -$-59.81M | $117.2M | -$-92.26M |
Line items
Line items
Line items
About Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
- CEO
- Patrick Amstutz
- Employees
- 134
- Beta
- 0.67
Explore
Frequently asked questions
What is the intrinsic value of Molecular Partners AG (MOLN)?
InvestorsCraft does not currently publish an intrinsic value for MOLN. How the IC value is calculated.
Is MOLN undervalued?
InvestorsCraft does not publish an undervaluation signal for MOLN at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.